Harper Investing’s AbbVie ABBV Stock Holding History

Harper Investing’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.56M	Buy	9,773 +1,025	+12%	+$263K	0.79%	39
2026 Q2	$2.2M	Buy	8,748 +1,829	+26%	+$394K	0.74%	40
2026 Q1	$1.5M	Buy	6,919 +5,717	+476%	+$1.27M	0.66%	37
2025 Q4	$275K	Buy	+1,202	New	+$274K	0.12%	56

Other funds holding ABBV

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $194B AUM 32.2% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Bahl & Gaynor Cincinnati, Ohio $21B AUM 23.02% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Harper Investing's ABBV Position: Q3 2026 in Review

Harper Investing increased its AbbVie (ABBV) stake by 12% in Q3 2026, buying an estimated $263K and bringing the position to 9,773 shares worth $2.56M. The position accounts for 0.79% of the portfolio, ranked #39.

Harper Investing first reported a position in ABBV in Q4 2025 and has held it in 4 quarters since. 2,565 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

Harper Investing held 9,773 shares of AbbVie worth $2.56M as of Q3 2026.
Harper Investing bought 1,025 AbbVie shares in Q3 2026, an estimated $263K.
AbbVie made up 0.79% of Harper Investing's portfolio in Q3 2026, its #39 holding.
Harper Investing first reported a position in AbbVie in Q4 2025 and has held it in 4 quarters since.
2,565 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Harper Investing's 13F filing for Q3 2026, filed 22 Oct 2026.